Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of lyophilised Lactobacillus crispatus IP174178 with metronidazole for bacterial vaginosis
2015-004563-37Phase 3Terminated
- Sponsor
- IPRAD Pharma
- Start
- Apr 2016
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of lactobacillus crispatus IP174178 in bacterial vaginosis (BV) (2 arms), sponsored by IPRAD Pharma. Primary endpoint: Normalisation of Amsel criteria at day 14. Started Apr 2016; status: terminated.
02
Drugs
lactobacillus crispatus IP174178
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on 2015-004563-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004563-37.